These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Golden opportunities. Smaglik P Nature; 2005 Jul; 436(7047):144-7. PubMed ID: 16007735 [No Abstract] [Full Text] [Related]
23. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery. Rai AK; Reichman JH; Uhlir PF; Crossman C Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492 [No Abstract] [Full Text] [Related]
24. Pharmacotherapy crisis in the spotlight--is open collaboration between academia and industry the answer? Kaski JC Cardiovasc Drugs Ther; 2011 Apr; 25(2):187-8. PubMed ID: 21503624 [No Abstract] [Full Text] [Related]
25. More fizz at Pfizer? Nature; 2006 Aug; 442(7104):734. PubMed ID: 16915258 [No Abstract] [Full Text] [Related]
26. Patent highlights October-November 2017. Mucke HA Pharm Pat Anal; 2018 Mar; 7(2):73-81. PubMed ID: 29417883 [TBL] [Abstract][Full Text] [Related]
29. 13th EGA annual conference. Challenges in the European and global environment for the generic medicines industry. Kuhrt K IDrugs; 2007 Aug; 10(8):549-53. PubMed ID: 17665329 [No Abstract] [Full Text] [Related]
30. Charles Hugh-Jones. Interview by Asher Mullard. Hugh-Jones C Nat Rev Drug Discov; 2013 Dec; 12(12):900. PubMed ID: 24287774 [No Abstract] [Full Text] [Related]
31. Cancer research in the United States: A critical review of current status and proposal for alternative models. Kantarjian HM; Prat F; Steensma DP; Kurzrock R; Stewart DJ; Sekeres MA; Leveque J Cancer; 2018 Jul; 124(14):2881-2889. PubMed ID: 29757456 [No Abstract] [Full Text] [Related]